Medical Communications
FDA publishes report stating Global Pharma’s eye drops broke safety norms
April 4, 2023 Medical Communications
The FDA has published a report revealing that Global Pharma’s plant in India’s Chennai city failed to achieve safety norms …
InnoCare announced first subject dosed in clinical trial of novel targeted protein degrader ICP-490
April 4, 2023 Medical Communications
InnoCare has announced that the first subject has been dosed in its clinical trial of its novel targeted protein degrader …
Merck receives FDA approval for Keytruda in combination with Padcev to treat bladder cancer
April 4, 2023 Medical Communications
Merck (known as MSD globally) has announced that it has received FDA approval for Keytruda in combination with Padcev for …
Pixium Vision’s Prima System granted FDA Breakthrough Device Designation
April 3, 2023 Medical Communications
French bioelectronics company Pixium Vision has been granted Breakthrough Device Designation by the FDA for its Prima System. Prima …
AstraZeneca’s NMOSD treatment recommended marketing authorisation by CHMP
April 3, 2023 Medical Communications
Pharma giant AstraZeneca has been given a recommendation by the EU’s Committee for Medicinal Products (CHMP) for marketing authorisation for …
Abbott gains FDA approval for Epic Max tissue valve for the treatment of aortic valve disease
March 31, 2023 Medical Communications
Abbott has announced that the FDA has approved its Epic Max stented tissue valve to treat patients with aortic regurgitation …
First over-the-counter opioid overdose treatment approved by FDA
March 31, 2023 Medical Communications
The FDA has announced that it has approve Narcan, 4mg naloxone hydrochloride nasal spray for over-the-counter (OTC), non-prescription use. This …
NEC streamlines AI drug development with subsidiary reshuffle
March 31, 2023 Medical Communications
Japan-based NEC Corporation has announced that it is realigning its subsidiaries in order to streamline its AI drug development services. …
Nanoscope Therapeutics announces positive results from phase 2b trial in Retinitis Pigmentosa
March 31, 2023 Medical Communications
US-based Nanoscope Therapeutics has announced topline results from its phase 2b RESTORE clinical trial. Currently, patients with vision loss due …
Hovione and Laxxon Medical sign partnership over 3D printed pharmaceutical applications
March 30, 2023 Medical Communications
Hovione, a CDMO, and Laxxon Medical, a pharma-technology company, have signed a strategic partnership deal to bring 3D printing technologies …
Genialis raises $13m in Series A funding for the development of AI/ML patient classifiers
March 29, 2023 Medical Communications
Genialis, a computational precision medicine company, has announced that it’s raised more than $13m in Series A funding, co-led by …
University of Dundee aids AI research for hypertension
March 29, 2023 Medical Communications
The University of Dundee has announced its involvement in a Europe-wide project which will study whether AI can improve the …
OctoVent and Orient EuroPharma sign licensing agreement over immunotherapeutic candidate
March 28, 2023 Medical Communications
OctoVent, subsidiary of Hepalink Pharmaceutical Group, has entered into a license agreement with Taiwan-based Orient EuroPharma (OEP). The two companies …
Abberior installs new STED microscope at MBC BioLabs
March 27, 2023 Medical Communications
Abberior has announced that it has placed a super-resolution STED microscope at MBC BioLabs, which is the leading San Francisco …
FDA releases draft of accelerated approval guidance for oncology therapeutics
March 27, 2023 Medical Communications
The FDA has released a draft of new guidance for accelerated approval for oncology therapeutics, highlighting the need for stricter …
Latest content
Acumentis CEO Herspiegel steps down as Burden assumes role
October 27, 2026
October 26, 2026
